8-K filings and company releases

Company news

3 articles on AbCellera Biologics.

Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first. Each one links to the filing or release it was written from.Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first.

Download on the App StoreGet it on Google Play

Free on iOS and Android

ABCL articles

Newest first, 25 to a page
  1. Aug 13, 2026 · Form 8-K

    AbCellera Biologics prices $200 million offering of common shares and pre-funded warrants

    AbCellera Biologics said gross proceeds are expected to be approximately $200 million, before underwriting discounts and offering expenses.

    Form 8-K
  2. Jul 6, 2026 · Form 8-K

    AbCellera Biologics appoints Lynn Seely to its board of directors

    Seely is president and CEO of Lyell Immunopharma Inc. and was previously CEO of Myovant Sciences Inc.

    Form 8-K
  3. Jun 12, 2026 · Form 8-K

    AbCellera Biologics shareholders elect two Class III directors

    The meeting covered 305,264,947 common shares outstanding and entitled to vote as of the April 15, 2026 record date.

    Form 8-K

How these are written

  • The source: the company's own 8-K filing or press release, linked from every article. What the company says is attributed to the company.
  • The checks: each article is written by GetSignal with AI and checked against its source before it is shown.
  • The date: the day the company filed the 8-K or published the release.
  • Not investment advice. An article reports what the company disclosed; it is not a view on the stock.